Novartis (VTX:NOVN) has been given a CHF 90 target price by equities researchers at Sanford C. Bernstein in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 14.83% from the stock’s current price.

Several other research firms have also recently issued reports on NOVN. Morgan Stanley set a CHF 92 price target on shares of Novartis and gave the stock a “buy” rating in a research note on Thursday, January 25th. JPMorgan Chase set a CHF 84 price target on shares of Novartis and gave the stock a “neutral” rating in a research note on Wednesday, January 10th. Societe Generale set a CHF 95 price target on shares of Novartis and gave the stock a “buy” rating in a research note on Wednesday, March 14th. S&P Global set a CHF 91 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Finally, Berenberg Bank set a CHF 91 target price on shares of Novartis and gave the stock a “neutral” rating in a research report on Friday, January 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of CHF 88.25.

Novartis stock opened at CHF 78.38 on Thursday. Novartis has a 12-month low of CHF 72.45 and a 12-month high of CHF 88.30.

COPYRIGHT VIOLATION WARNING: “Novartis (NOVN) PT Set at CHF 90 by Sanford C. Bernstein” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2018/04/19/novartis-novn-pt-set-at-chf-90-by-sanford-c-bernstein.html.

Novartis Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.